ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
8 |
04/03/21 |
04/03/21 |
ASX - By Stock
|
322
|
95K
|
8
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
1 |
04/03/21 |
04/03/21 |
ASX - By Stock
|
322
|
95K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
2 |
04/03/21 |
04/03/21 |
ASX - By Stock
|
322
|
95K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
5 |
01/03/21 |
01/03/21 |
ASX - By Stock
|
322
|
95K
|
5
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
6 |
01/03/21 |
01/03/21 |
ASX - By Stock
|
322
|
95K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
6 |
01/03/21 |
01/03/21 |
ASX - By Stock
|
322
|
95K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
1 |
25/02/21 |
25/02/21 |
ASX - By Stock
|
322
|
95K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
2 |
25/02/21 |
25/02/21 |
ASX - By Stock
|
322
|
95K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
2 |
24/02/21 |
24/02/21 |
ASX - By Stock
|
322
|
95K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
4 |
24/02/21 |
24/02/21 |
ASX - By Stock
|
322
|
95K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
1 |
24/02/21 |
24/02/21 |
ASX - By Stock
|
322
|
95K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
6 |
24/02/21 |
24/02/21 |
ASX - By Stock
|
322
|
95K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
3 |
24/02/21 |
24/02/21 |
ASX - By Stock
|
322
|
95K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
9 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
322
|
95K
|
9
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
7 |
22/02/21 |
22/02/21 |
ASX - By Stock
|
322
|
95K
|
7
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
10 |
22/02/21 |
22/02/21 |
ASX - By Stock
|
322
|
95K
|
10
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
3 |
19/02/21 |
19/02/21 |
ASX - By Stock
|
322
|
95K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
3 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
322
|
95K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
3 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
322
|
95K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
5 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
322
|
95K
|
5
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
6 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
322
|
95K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
3 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
322
|
95K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
4 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
322
|
95K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
12 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
322
|
95K
|
12
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
1 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
322
|
95K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
9 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
322
|
95K
|
9
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
2 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
322
|
95K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International seeks FDA approval for PromarkerD
|
|
no vice
|
322 |
95K |
7 |
09/02/21 |
09/02/21 |
ASX - By Stock
|
322
|
95K
|
7
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: December 2020 Quarterly Activities Report and Appendix 4C
|
|
no vice
|
19 |
5.9K |
6 |
31/01/21 |
31/01/21 |
ASX - By Stock
|
19
|
5.9K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: December 2020 Quarterly Activities Report and Appendix 4C
|
|
no vice
|
19 |
5.9K |
0 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
19
|
5.9K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: December 2020 Quarterly Activities Report and Appendix 4C
|
|
no vice
|
19 |
5.9K |
0 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
19
|
5.9K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: December 2020 Quarterly Activities Report and Appendix 4C
|
|
no vice
|
19 |
5.9K |
4 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
19
|
5.9K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Research report and Initiation of coverage by Euroz
|
|
no vice
|
26 |
10K |
1 |
27/01/21 |
27/01/21 |
ASX - By Stock
|
26
|
10K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Research report and Initiation of coverage by Euroz
|
|
no vice
|
26 |
10K |
2 |
14/01/21 |
14/01/21 |
ASX - By Stock
|
26
|
10K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Research report and Initiation of coverage by Euroz
|
|
no vice
|
26 |
10K |
3 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
26
|
10K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: AGM Investor Presentation
|
|
no vice
|
22 |
5.8K |
14 |
26/11/20 |
26/11/20 |
ASX - By Stock
|
22
|
5.8K
|
14
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Middle East is next market for PromarkerD immunoassay test
|
|
no vice
|
44 |
9.5K |
9 |
14/11/20 |
14/11/20 |
ASX - By Stock
|
44
|
9.5K
|
9
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Middle East is next market for PromarkerD immunoassay test
|
|
no vice
|
44 |
9.5K |
0 |
13/11/20 |
13/11/20 |
ASX - By Stock
|
44
|
9.5K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Middle East is next market for PromarkerD immunoassay test
|
|
no vice
|
44 |
9.5K |
2 |
12/11/20 |
12/11/20 |
ASX - By Stock
|
44
|
9.5K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: PromarkerD clinical assay performance results published
|
|
no vice
|
24 |
3.9K |
7 |
05/11/20 |
05/11/20 |
ASX - By Stock
|
24
|
3.9K
|
7
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: PromarkerD clinical assay performance results published
|
|
no vice
|
24 |
3.9K |
5 |
05/11/20 |
05/11/20 |
ASX - By Stock
|
24
|
3.9K
|
5
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
no vice
|
18 |
4.8K |
2 |
03/11/20 |
03/11/20 |
ASX - By Stock
|
18
|
4.8K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International raises $6m in successful Placement
|
|
no vice
|
35 |
8.2K |
1 |
26/10/20 |
26/10/20 |
ASX - By Stock
|
35
|
8.2K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Proteomics International raises $6m in successful Placement
|
|
no vice
|
35 |
8.2K |
2 |
26/10/20 |
26/10/20 |
ASX - By Stock
|
35
|
8.2K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: PromarkerD international validation study results published
|
|
no vice
|
28 |
6.8K |
5 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
28
|
6.8K
|
5
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: PromarkerD international validation study results published
|
|
no vice
|
28 |
6.8K |
4 |
16/10/20 |
16/10/20 |
ASX - By Stock
|
28
|
6.8K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: PromarkerD international validation study results published
|
|
no vice
|
28 |
6.8K |
4 |
16/10/20 |
16/10/20 |
ASX - By Stock
|
28
|
6.8K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: PromarkerD international validation study results published
|
|
no vice
|
28 |
6.8K |
6 |
16/10/20 |
16/10/20 |
ASX - By Stock
|
28
|
6.8K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Annual Report to shareholders
|
|
no vice
|
51 |
15K |
5 |
14/10/20 |
14/10/20 |
ASX - By Stock
|
51
|
15K
|
5
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Change of Director's Interest Notice
|
|
no vice
|
11 |
3.8K |
3 |
08/10/20 |
08/10/20 |
ASX - By Stock
|
11
|
3.8K
|
3
|
|